DHR

Danaher Schedules Fourth Quarter 2023 Earnings Conference Call

Retrieved on: 
Thursday, December 21, 2023

WASHINGTON, Dec. 21, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2023 on Tuesday, January 30, 2024 beginning at 8:00 a.m.

Key Points: 
  • WASHINGTON, Dec. 21, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2023 on Tuesday, January 30, 2024 beginning at 8:00 a.m.
  • ET and notifying the operator that you are dialing in for Danaher's earnings conference call (Conference ID: DHRQ423).
  • A replay of the conference call will be available shortly after the conclusion of the call until February 13, 2024.
  • Danaher's earnings press release, the webcast slides and other related materials will be posted to the "Investors" section of Danaher's website under the subheading "Quarterly Earnings" beginning at 6:00 a.m.

Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales

Retrieved on: 
Monday, December 4, 2023

The circular in relation to the Scheme was published or made available to Scheme Shareholders on October 5, 2023 (the ‘Scheme Circular‘).

Key Points: 
  • The circular in relation to the Scheme was published or made available to Scheme Shareholders on October 5, 2023 (the ‘Scheme Circular‘).
  • Abcam is pleased to announce that the Court has today issued the Court Order sanctioning the Scheme.
  • The last day of trading in Abcam ADSs on Nasdaq is expected to be December 5, 2023, with trading in Abcam ADSs on Nasdaq being suspended by 8.00 a.m. (Eastern Time) on December 6, 2023.
  • Capitalized terms used in this announcement shall, unless otherwise defined, have the same meanings as set out in the Scheme Circular.

Abcam Acquisition by Danaher Has Received All Identified Clearances; Transaction Expected to Close on December 6, 2023

Retrieved on: 
Friday, November 17, 2023

The Court Hearing at which the Court will be asked to sanction the Scheme has been scheduled to be held on December 4, 2023.

Key Points: 
  • The Court Hearing at which the Court will be asked to sanction the Scheme has been scheduled to be held on December 4, 2023.
  • An updated expected timetable of principal events is set out below.
  • Capitalized terms in this announcement, unless otherwise defined, have the same meanings as set out in the Scheme Circular.
  • by 8.00 a.m. (Eastern Time) on December 6, 2023
    as soon as practicable after the Effective Time, and in any event not later than five Business Days after the Effective Time

Danaher Announces Quarterly Dividend

Retrieved on: 
Tuesday, December 5, 2023

WASHINGTON, Dec. 5, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.24 per share of its common stock, payable on January 26, 2024 to holders of record on December 29, 2023.

Key Points: 

WASHINGTON, Dec. 5, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.24 per share of its common stock, payable on January 26, 2024 to holders of record on December 29, 2023.

Danaher to Present at Evercore ISI HealthCONx Conference

Retrieved on: 
Tuesday, November 21, 2023

WASHINGTON, Nov. 21, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Evercore ISI HealthCONx Conference in Miami, Florida on Wednesday, November 29, 2023 at 3:00 p.m.

Key Points: 
  • WASHINGTON, Nov. 21, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Evercore ISI HealthCONx Conference in Miami, Florida on Wednesday, November 29, 2023 at 3:00 p.m.
  • ET.
  • The event will be simultaneously webcast on www.danaher.com .

Statement from Dr. Jonathan Milner on the suspension of the “Vote AGAINST” campaign

Retrieved on: 
Wednesday, November 1, 2023

“After extensive feedback from the majority of Abcam’s shareholders, I have today decided to suspend my “Vote AGAINST” campaign.

Key Points: 
  • “After extensive feedback from the majority of Abcam’s shareholders, I have today decided to suspend my “Vote AGAINST” campaign.
  • It has become clear that a significant majority intend to support Danaher's acquisition of Abcam and I respect this decision and will not stand in the way of the deal.
  • Although this outcome is not what I envisioned, I accept the result and wish Abcam and Danaher all the best for their future.
  • A special thanks also goes to my team of advisors who, acting with integrity and honesty, ensured every shareholder's voice was heard.

Shareholders of Abcam Approve Proposed Acquisition by Danaher

Retrieved on: 
Monday, November 6, 2023

Abcam plc (Nasdaq: ABCM) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, which entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE: DHR) (‘Danaher’), today announced that its shareholders have approved the proposal for Danaher to acquire all of the outstanding shares of Abcam for $24.00 per share in cash (the ‘Transaction’).

Key Points: 
  • Abcam plc (Nasdaq: ABCM) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, which entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE: DHR) (‘Danaher’), today announced that its shareholders have approved the proposal for Danaher to acquire all of the outstanding shares of Abcam for $24.00 per share in cash (the ‘Transaction’).
  • “With this approval, we are focused on moving swiftly toward transaction close and ensuring a successful transition to deliver maximum value to our shareholders, employees, and customers.”
    “We are thrilled shareholders have overwhelmingly approved the Transaction.
  • This outcome has arrived at the right time for Abcam to embark on the next chapter in its story within the Danaher family,” said Alan Hirzel, Chief Executive Officer of Abcam.
  • The Resolution was therefore passed by the requisite majority of Abcam Shareholders.

Danaher appoints Christopher Riley to Executive Vice President for Biotechnology

Retrieved on: 
Tuesday, October 31, 2023

WASHINGTON, Oct. 31, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Christopher Riley has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Biotechnology business, effective January 1, 2024.

Key Points: 
  • WASHINGTON, Oct. 31, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Christopher Riley has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Biotechnology business, effective January 1, 2024.
  • Mr. Riley, currently Vice President and Group Executive of Danaher's Life Sciences company with responsibility for Genomic Medicines, will become an executive officer of Danaher reporting to President and Chief Executive Officer, Rainer Blair.
  • His strong track record of delivering results, passion for helping our customers and building winning teams, plus his deep commitment to the Danaher Business System, is a tremendous asset for Danaher.
  • Previously he was Vice President and Group Executive for Danaher's Diagnostics company and, prior to that, held various roles of increasing responsibility across multiple Danaher subsidiaries.

Integrated DNA Technologies Opens New Therapeutic Manufacturing Facility to Support Growing Demand in Genomic Medicine

Retrieved on: 
Tuesday, October 17, 2023

Global genomics solutions provider Integrated DNA Technologies (IDT), an operating company in the Life Sciences segment of Danaher Corporation (NYSE:DHR), today announced the completion of its new Therapeutic Oligonucleotide Manufacturing facility in Coralville, Iowa.

Key Points: 
  • Global genomics solutions provider Integrated DNA Technologies (IDT), an operating company in the Life Sciences segment of Danaher Corporation (NYSE:DHR), today announced the completion of its new Therapeutic Oligonucleotide Manufacturing facility in Coralville, Iowa.
  • These new capabilities and offerings will be supported with comprehensive documentation and testing, a support team, and regulatory guidance to help accelerate researchers’ path to the clinic.
  • As a pioneer in genome editing, IDT’s continued investments will enable customers to rapidly move from clinical development to commercialization.
  • Mortenson Company, a team led by OPN Architects and Barr Engineering Co. on the facility design and construction of its cGMP facility.

Independent Directors of Abcam Highlight Compelling Reasons for Shareholders to Support Proposed Sale to Danaher

Retrieved on: 
Thursday, October 12, 2023

We are writing to you today as the independent non-executive directors of Abcam’s Board of directors to affirm that this agreement was the result of a rigorous, fair and competitive sale process.

Key Points: 
  • We are writing to you today as the independent non-executive directors of Abcam’s Board of directors to affirm that this agreement was the result of a rigorous, fair and competitive sale process.
  • We unanimously support this Transaction as we believe it is the best deal available and is in the best interests of Abcam and its shareholders.
  • Ultimately, if this Transaction were not approved by shareholders, it is uncertain what path Abcam would be on next.
  • We need your support to secure a positive outcome for all Abcam shareholders.